Combined oral thalidomide with liposomal doxorubicin in the treatment of recurrent epithelial ovarian and primary peritoneal cancers

Guo Hongyan

DOI: https://doi.org/10.3969/j.issn.1004-7379.2008.02.009

2008-01-01

Abstract:Objective:To evaluate the toxicity and clinical activity of combined oral thalidomide and liposomal doxorubicin in the treatment of patients with recurrent epithelial ovarian or primary peritoneal carcinoma.Methods:All of the nine patients underwent primary debulking followed by adjuvant chemotherapy with Paclitaxel and Carboplatin.Upon relapse,patients were treated with liposomal doxorubicin 30~50mg/m2 every four weeks combined with escalating doses of thalidomide about 100~300mg/d,starting at 100mg/day,increasing by 50~100mg every two weeks.Patients were evaluated with physical exam,imaging studies,and CA125 levels.Results:Nine patients (median age 56) with recurrent epithelial ovarian cancer or peritoneal cancer were evaluated; of which,one had FIGO stage ⅢB,six had stage ⅢC,and two had stage IV disease.The median number of cycles of combination of oral thalidomide and liposomal doxorubicin was six with a median follow-up time of 18.5 months.The most common adverse effects were fatigue (55.6%) and neuropathy (55.6%).Grade 3 events included one with fatigue,one with an allergic rash and one with neuropathy.Based on the RECIST criteria/evaluation of the six patients with measurable disease,two had a partial response,two had stable disease,one had progressive disease,and one was lost to follow-up.Of the the other two women with chemical recurrence based on CA125 levels,all had at least 50% reduction in CA125 after 3~4 cycles of combined treatment of thalidomide and liposomal doxorubicin.One patient was undertaken a secondary tumor debulking before the chemotherapy was given and in the 36 months follow-up no evidence of tumor recurrence.The median progression-free survival time was 6.5 months with a median overall survival of 20.5 months.Conclusion:The combination of oral thalidomide and liposomal doxorubicin has an acceptable toxicity.Future studies are needed to determine the clinical activity of oral thalidomide combined with cytotoxic chemotherapy.